Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Metastatic biopsy programmes combined with advances in genomic sequencing have
provided new insights into the molecular landscape of castration-resistant prostate cancer …

A major hurdle in the study of rare tumors is a lack of existing preclinical models.
Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of …

Although a de novo clinical presentation of small cell neuroendocrine carcinoma of the
prostate is rare, a subset of patients previously diagnosed with prostate adenocarcinoma …

Prostate cancer (PCa) remains a leading cause of mortality among men in the United States
and Western Europe. The molecular mechanism of PCa pathogenesis has not been fully …

Androgen deprivation therapy (ADT) is the mainstay treatment for advanced prostate cancer
(PC). Most patients eventually progress to a condition known as castration-resistant prostate …

Background Neuroendocrine carcinomas of the prostate (NEPCs) are rare tumors with poor
prognosis. While platinum and etoposide-based chemotherapy regimens (PE) are …

Introduction: Disease progression despite androgen suppression defines lethal castration-
resistant prostate cancer (CRPC). Most of these cancers remain androgen receptor (AR) …

Prostate cancer initiation, development and progression is driven by androgen receptor (AR)
signaling. Androgen deprivation therapy is the primary treatment for patients that present …

Context.—Aggressive variant prostate cancer (AVPCa) develops in a subset of patients with
metastatic castration-resistant prostate cancer. The clinical and histologic overlap of AVPCa …